September 30, 2005 -- Exjade from Novartis was recommended to treat blood transfusion patients, Cardiome Pharma said RSD1235 helped patients suffering from atrial fibrillation, NeoPharm said its reformulated version of paclitaxel was effective, a staph vaccine from Nabi met its endpoints, Bestaseron from Schering delayed the onset of MS symptoms by one year, Progenics and Cytogen released positive mouse study data about a novel prostate drug, Salix and InKine Pharma will close their merger today, Altana will buy the US dermatology division of GlaxoSmithKline, and Hollis-Eden Pharma lost 37.5% of its value after news showed the government intends to buy only 100,000 doses of its anti-radiation vaccine. The Centient Biotech 200 was 16 points higher at 3758, a gain of .42%. More details...
